Stockscreener 앱 받기
40.61
3.81%
-1.61
시간 외 거래:
40.92
0.31
+0.76%
전일 마감가:
$42.22
열려 있는:
$42.71
하루 거래량:
1.58M
Relative Volume:
0.83
시가총액:
$3.47B
수익:
$170.10M
순이익/손실:
$-239.59M
주가수익비율:
-14.50
EPS:
-2.8
순현금흐름:
$-191.20M
1주 성능:
-3.40%
1개월 성능:
-4.29%
6개월 성능:
-17.68%
1년 성능:
-39.28%
1일 변동 폭
$40.54
$42.88
1주일 범위
$39.21
$43.00
52주 변동 폭
$36.52
$91.10
크리스퍼 테라퓨틱스 Stock (CRSP) Company Profile
명칭
Crispr Therapeutics Ag
전화
(617) 315-4600
주소
BAARERSTRASSE 14, ZUG
CRSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
40.61 | 3.47B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
크리스퍼 테라퓨틱스 Stock (CRSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-03 | 개시 | H.C. Wainwright | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-08-02 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-28 | 재개 | Guggenheim | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-11 | 다운그레이드 | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 개시 | Mizuho | Buy |
| 2023-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-04-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2023-03-07 | 개시 | Robert W. Baird | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-08-09 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-04-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-10 | 재확인 | Chardan Capital Markets | Buy |
| 2020-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-10 | 재확인 | Needham | Buy |
| 2020-12-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-07-28 | 재확인 | Needham | Buy |
| 2020-07-14 | 개시 | SunTrust | Buy |
| 2020-06-15 | 재확인 | Canaccord Genuity | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-19 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 개시 | Jefferies | Buy |
| 2019-07-26 | 개시 | Canaccord Genuity | Buy |
| 2019-06-10 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-14 | 개시 | William Blair | Mkt Perform |
| 2019-01-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
모두보기
크리스퍼 테라퓨틱스 주식(CRSP)의 최신 뉴스
CRISPR Therapeutics AG (CRSP): Among Cathie Wood’s Top Stock Picks for 2025 - Insider Monkey
HC Wainwright Begins Coverage on CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
March 28th Options Now Available For CRISPR Therapeutics (CRSP) - Nasdaq
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.3%Should You Sell? - MarketBeat
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today - MSN
KBC Group NV Has $2.38 Million Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
FY2024 Earnings Estimate for CRSP Issued By HC Wainwright - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 2%Here's Why - MarketBeat
Crispr Therapeutics: Why I’ve Become Even More Bullish (Rating Upgrade) (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics (NASDAQ:CRSP) Trading 3.7% HigherStill a Buy? - MarketBeat
Gene Editing Therapy Casgevy Now Funded In 8 Countries But French Access Withdrawn - Pink Sheet
Analysts Offer Predictions for CRSP FY2024 Earnings - MarketBeat
(CRSP) Trading Report - Stock Traders Daily
CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 1.2%What's Next? - MarketBeat
HC Wainwright & Co. Initiates Coverage of CRISPR Therapeutics (CRSP) with Buy Recommendation - MSN
Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates? - Yahoo Finance
HC Wainwright Initiates CRISPR Therapeutics at Buy With $65 Price Target -February 03, 2025 at 07:40 am EST - Marketscreener.com
HC Wainwright Initiates Coverage on CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG: A Compelling Buy Amidst Gene Editing Innovation and Market Growth Potential - TipRanks
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 0.7%Here's Why - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Short Interest Update - MarketBeat
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? - The Motley Fool
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 0.8%Here's What Happened - MarketBeat
Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England - MSN
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 0.5%Still a Buy? - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 2.7%What's Next? - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Holdings Trimmed by Patriot Financial Group Insurance Agency LLC - MarketBeat
Slow Capital Inc. Lowers Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Cathie Wood's Ark Invest Bets On Biotech With CRISPR Therapeutics Investment, Exits Roblox - Benzinga
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.1%Time to Sell? - MarketBeat
Jim Cramer Says “CRISPR (CRSP) Keeps Losing Money Like Moderna” – Here’s Why - Yahoo Finance
CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference - GlobeNewswire
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors - MSN
CRISPR Therapeutics Readies Major Gene Therapy Updates for Guggenheim Conference - StockTitan
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 2.7%Here's What Happened - MarketBeat
Following a 34% decline over last year, recent gains may please CRISPR Therapeutics AG (NASDAQ:CRSP) institutional owners - Simply Wall St
Analysts Set CRISPR Therapeutics AG (NASDAQ:CRSP) Target Price at $78.38 - MarketBeat
CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last? - MSN
(CRSP) Proactive Strategies - Stock Traders Daily
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know - MSN
FY2024 EPS Estimates for CRSP Increased by Leerink Partnrs - MarketBeat
CRSP March 7th Options Begin Trading - Nasdaq
MaxCyte: Building the Future of Cell and Gene Therapy Innovation - Benzinga
Cantor Fitzgerald Estimates CRSP FY2025 Earnings - MarketBeat
크리스퍼 테라퓨틱스 (CRSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.82%
0.53%
자본화:
|
볼륨(24시간):